Compare CoreWeave (CRWV) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CoreWeave vs GSK plc — how do they compare? CoreWeave trades at $82.37 (market cap $44.99B), while GSK plc trades at $46.54 (market cap $91.88B). The key difference: GSK plc is far larger — about 2× CoreWeave's market cap, and GSK plc pays a 3.9% dividend while CoreWeave pays none. Which is the better fit depends on your goals — on Pluang, investors hold CoreWeave for 7 Days and GSK plc for 93 Days on average.
| CRWV | GSK | |
|---|---|---|
Market Cap | $44.99B | $91.88B |
Volume | 41,993,776 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $143.08 | $61.18 |
52-Week Low | $60.82 | $43.24 |
Typical Hold Time | 7 Days | 93 Days |
Enterprise Value | $91.06B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRWV trades at $82.08, down 7.2% amid a broader AI stock sell-off. The technical picture is bearish, with price below key resistance levels. Fundamentally, the company shows strong revenue growth but deep losses, with a net income margin of -25.4% in 2026. A massive $104 billion backlog signals high demand, yet expansion requires significant debt and equity financing, increasing financial risk.
The outlook is polarized: high growth potential from AI infrastructure demand contrasts with substantial execution and financial risks. Analyst consensus is bullish with a $147.57 price target, but investors face volatility from debt-funded expansion and competitive pressures. The stock's trajectory hinges on converting its backlog to profitable revenue.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CoreWeave
CoreWeave provides cloud computing infrastructure designed for AI workloads. Its platform gives organizations access to large-scale GPU computing and cloud services for training and running AI models.
Read more on CRWV →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
